Avastin and Taxotere for Esophagogastric Cancer

Bevacizumab will be administered intravenously in an outpatient clinic once a week, every
other week. Docetaxel will also be administered intravenously in the outpatient clinic once a
week for three out of four weeks. Blood tests and vital signs will be performed weekly.

After the first eight weeks of therapy a CT scan will be performed to determine and assess
the progress of the disease. If therapy is continued, radiological procedures will be
performed at week 16 and every 8 weeks thereafter.

Treatment will be given for a minimum of 8 weeks, as long as the patient does not experience
unacceptable side effects. Chemotherapy will continue for a year and a half as long as the
cancer is responding and there are no unacceptable side effects.

Inclusion Criteria:

- Histologically confirmed, unresectable or metastatic stage IV esophageal or gastric
carcinoma

- Measurable disease greater than or equal to 1cm by spiral computed tomography (CT)
scan or greater than or equal to 2cm by other radiographic technique

- ECOG performance status 0-2

- One prior chemotherapy for metastatic disease permitted

- White blood cell count greater than or equal to 3,000/mm

- Absolute neutrophil count greater than or equal to 1,500/mm3

- Platelet count greater than or equal to 100,000/mm3

- Hemoglobin greater than or equal to 8.0g/dl

- Creatinine less than 2.0mg/dL

- Total bilirubin less than 1.9mg/dL

Exclusion Criteria:

- Pregnant or lactating women

- History or evidence of central nervous system (CNS) disease

- Other active malignancies other than non-melanoma skin cancer or in-situ cervical
cancer

- History of severe hypersensitivity to docetaxel, bevacizumab or drugs formulated with
polysorbate 80.

- Current, recent or planned treatment with standard chemotherapy, radiation therapy or
another experimental therapy.

- History of other disease or metabolic dysfunction.

- Serious, non-healing wound, ulcer, or bone fracture.